The clinical trial of G-CSF priemed low-dose dicitabine in the prophylaxis of high risk acute myeloid leukemia relapse after allogenetic hematopoietic stem cell transplantation

Trial Profile

The clinical trial of G-CSF priemed low-dose dicitabine in the prophylaxis of high risk acute myeloid leukemia relapse after allogenetic hematopoietic stem cell transplantation

Recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Apr 2016

At a glance

  • Drugs Decitabine (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 28 Apr 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top